HDAC7 controls anti-viral and anti-tumor immunity by CD8+ T cells - Scorecard - MDSpire

HDAC7 controls anti-viral and anti-tumor immunity by CD8+ T cells

  • By

  • Cansu Yerinde

  • Jacqueline Keye

  • Hsiang-Jung Hsiao

  • Sibel Durlanik

  • Inka Freise

  • Franziska Nowak

  • Marilena Letizia

  • Stephan Schlickeiser

  • Benedikt Obermayer

  • Adrian Huck

  • Marie Friedrich

  • Hao Wu

  • Désirée Kunkel

  • Anja A. Kühl

  • Sebastian Bauer

  • Andreas Thiel

  • Ahmed N. Hegazy

  • Britta Siegmund

  • Rainer Glauben

  • Carl Weidinger

  • May 12, 2026

  • 0 min

Share

Clinical Scorecard: HDAC7 Regulates CD8+ T Cell Functions in Anti-Viral and Anti-Tumor Immunity

At a Glance

CategoryDetail
ConditionCD8+ T cell dysfunction and exhaustion
Key MechanismsRegulation of apoptosis, immune checkpoint expression, and metabolic homeostasis
Target PopulationMurine models of CD8+ T cell responses
Care SettingPreclinical research

Key Highlights

  • HDAC7 is essential for CD8+ T cell survival and function.
  • Absence of HDAC7 leads to increased apoptosis and immune checkpoint expression.
  • HDAC7 regulates metabolic fitness in CD8+ T cells.
  • Compromised anti-tumor responses observed in Hdac7 knockout mice.
  • HDAC7 is pivotal for memory recall responses in viral infections.

Guideline-Based Recommendations

Diagnosis

  • Evaluate CD8+ T cell functionality and exhaustion markers.

Management

  • Consider targeting HDAC7 pathways to enhance CD8+ T cell responses.

Monitoring & Follow-up

  • Assess immune checkpoint expression and metabolic profiles in CD8+ T cells.

Risks

  • Increased susceptibility to tumor progression and chronic infections due to T cell exhaustion.

Patient & Prescribing Data

Not applicable; study conducted in murine models.

Potential for HDAC7 modulation in enhancing anti-tumor and anti-viral immunity.

Clinical Best Practices

  • Monitor metabolic changes in CD8+ T cells during immune responses.
  • Investigate the role of epigenetic regulators in T cell differentiation.
  • Explore therapeutic strategies targeting HDAC7 in cancer immunotherapy.

Related Resources & Content

Original Source(s)

HDAC7 controls anti-viral and anti-tumor immunity by CD8+ T cells

  • by Cansu Yerinde, Jacqueline Keye, Hsiang-Jung Hsiao, Sibel Durlanik, Inka Freise, Franziska Nowak, Marilena Letizia, Stephan Schlickeiser, Benedikt Obermayer, Adrian Huck, Marie Friedrich, Hao Wu, Désirée Kunkel, Anja A. Kühl, Sebastian Bauer, Andreas Thiel, Ahmed N. Hegazy, Britta Siegmund, Rainer Glauben, Carl Weidinger

  • May 12, 2026

Related Content

Anatomy-aware lymphoma lesion detection in whole-body PET/CT

Dana-Farber Research Helps Drive FDA Label Update for Primary CNS Lymphoma

Change removes prior exclusion and may expand access to CAR T-cell therapy for eligible relapsed or refractory patients

  • by

  • February 9, 2026

  • 3 min
Delays in Hematology Consultations and Non-Hematology Referrals in Blood Cancer Diagnosis: Insights from a Comprehensive National Survey in Australia